Home»Exposition»Rewind Therapeutics Awarded €2.9 Million VLAIO Grant to Discover and Develop Novel Drug Candidates for Myelin-related Neurological Diseases

Rewind Therapeutics Awarded €2.9 Million VLAIO Grant to Discover and Develop Novel Drug Candidates for Myelin-related Neurological Diseases

0
Shares
Pinterest Google+

LEUVEN, Belgium, Aug. 1, 2019 /PRNewswire/ — Rewind Therapeutics (“Rewind”), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for myelin-related diseases such as multiple sclerosis, announces it will lead a new industry-academic R&D…

Previous post

Netskope Cloud Report™ Finds 85% of All Enterprise Web Traffic Used For Cloud Services

Next post

CBIO Brand Development Releases New Video for its Armourgenix™ Sport Hemp-Infused Product Line With Professional Football Player Ebo Ogundeko